诚达药业11月6日获融资买入1462.49万元，融资余额2.47亿元

Group 1 - The core viewpoint of the news is that Chengda Pharmaceutical has shown mixed financial performance, with a notable increase in revenue but a significant decline in net profit [2] - As of November 6, 2023, Chengda Pharmaceutical's stock price increased by 0.93%, with a trading volume of 95.18 million yuan and a net financing outflow of 717,800 yuan [1] - The company's financing balance reached 247 million yuan, accounting for 5.09% of its market capitalization, indicating a high level of financing activity compared to the past year [1] Group 2 - For the period from January to September 2023, Chengda Pharmaceutical reported a revenue of 285 million yuan, representing a year-on-year growth of 16.95% [2] - The net profit attributable to the parent company was 16.77 million yuan, reflecting a year-on-year decrease of 58.47% [2] - The number of shareholders decreased by 8.58% to 12,700, while the average circulating shares per person increased by 36.16% to 8,577 shares [2] Group 3 - Since its A-share listing, Chengda Pharmaceutical has distributed a total of 133 million yuan in dividends, with 89.62 million yuan paid out over the last three years [3]